The study will provide insights into which medication can be used at what point in time to reduce the risk of dementia and/or slow down the development of dementia. The results will also provide a basis for even better recognition and measurement of the first signs of dementia. The results are expected over the next four years.
The parties collaborating on this study are: Amsterdam UMC (VUmc and AMC) (Amsterdam Dementia Cohort, EPAD+, Longitudinal Aging Study Amsterdam), Erasmus MC (Rotterdam Study), LUMC (Leiden Longevity Study), MUMC+ (Maastricht Study), RIVM (Doetinchem Cohort Study), UMCG (Lifelines) and UMC Utrecht (SMART-MR Study). The study is funded by the Netherlands Organisation for Health Research and Development and Alzheimer Nederland.